Fycompa Approved for Epileptic Seizures
MONDAY, Oct. 22 (HealthDay News) -- Fycompa (perampanel) tablets have been approved by the U.S. Food and Drug Administration to treat partial onset seizures in people aged 12 and older who have epilepsy.
Partial onset seizures are the most common seizures in people with epilepsy, a disorder commonly triggered by overactive nerve cells in the brain. Symptoms may include spasms, unusual behavior and loss of consciousness, the FDA said Monday in a news release.
The most common side effects of Fycompa reported during clinical trials included dizziness, sleepiness, irritability, falls, upper respiratory infections and weight gain.
Fycompa's label warns of the possibility of more serious side effects, including aggression, anger, anxiety, paranoia, euphoria and agitation.
The drug is produced by Eisai Inc., of Woodcliff Lake, N.J.
More information
The U.S. National Library of Medicine has more about epilepsy.
Related Articles- Revised Sunscreen Labels Should Help Consumers Make Wiser Choices
May 20, 2013 - Test Approved to Detect Faulty Lung Cancer Gene
May 16, 2013
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright ©2012 HealthDay. All rights reserved.
Sharp HealthCare is a 2007 Malcolm Baldrige National Quality Award Recipient